{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T20:08:52Z","timestamp":1791662932954,"version":"4.3.4"},"reference-count":53,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000048","name":"American Cancer Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000048","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005301","name":"American College of Surgeons","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005301","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.leukres.2025.108086","type":"journal-article","created":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T21:10:14Z","timestamp":1755551414000},"page":"108086","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Treatment patterns and survival outcomes for very elderly patients with acute myeloid leukemia: A National Cancer Database study"],"prefix":"10.1016","volume":"157","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8156-9597","authenticated-orcid":false,"given":"Tina Y.","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6595-1822","authenticated-orcid":false,"given":"Alex Y.","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7906-4856","authenticated-orcid":false,"given":"Mara M.","family":"Epstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8208-1902","authenticated-orcid":false,"given":"Shyam A.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2025.108086_bib1","unstructured":"SEER*Explorer Application. \u3008https:\/\/seer.cancer.gov\/statistics-network\/explorer\/application.html\u3009."},{"issue":"12","key":"10.1016\/j.leukres.2025.108086_bib2","doi-asserted-by":"crossref","first-page":"e578","DOI":"10.3324\/haematol.2018.196691","article-title":"Acute myeloid leukemia in very old patients","volume":"103","author":"Lazarevic","year":"2018","journal-title":"Haematologica"},{"issue":"12","key":"10.1016\/j.leukres.2025.108086_bib3","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.3324\/haematol.2012.066100","article-title":"Survival for older patients with acute myeloid leukemia: a population-based study","volume":"97","author":"Oran","year":"2012","journal-title":"Haematologica"},{"issue":"9","key":"10.1016\/j.leukres.2025.108086_bib4","doi-asserted-by":"crossref","first-page":"3481","DOI":"10.1182\/blood-2005-09-3724","article-title":"Age and acute myeloid leukemia","volume":"107","author":"Appelbaum","year":"2006","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.leukres.2025.108086_bib5","doi-asserted-by":"crossref","first-page":"2720","DOI":"10.1002\/cncr.28129","article-title":"Outcome of older patients with acute myeloid leukemia: an analysis of SEER data over 3 decades","volume":"119","author":"Thein","year":"2013","journal-title":"Cancer"},{"issue":"11","key":"10.1016\/j.leukres.2025.108086_bib6","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.3324\/haematol.2018.191536","article-title":"Genetics of acute myeloid leukemia in the elderly: mutation spectrum and clinical impact in intensively treated patients aged 75 years or older","volume":"103","author":"Prassek","year":"2018","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.leukres.2025.108086_bib7","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.beha.2018.09.010","article-title":"Patterns of mutations in TP53 mutated AML","volume":"31","author":"Welch","year":"2018","journal-title":"Best. Pr. Res Clin. Haematol."},{"issue":"12","key":"10.1016\/j.leukres.2025.108086_bib8","doi-asserted-by":"crossref","first-page":"2544","DOI":"10.1038\/s41375-024-02417-1","article-title":"Managing the unmanageable: evidence-driven approaches to real-world patient prototypes of TP53-mutant myelodysplastic neoplasms and acute myeloid leukemia","volume":"38","author":"Patel","year":"2024","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.leukres.2025.108086_bib9","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1002\/jha2.791","article-title":"Prognostic heterogeneity and clonal dynamics within distinct subgroups of myelodysplastic syndrome and acute myeloid leukemia with tp53 disruptions","volume":"4","author":"Patel","year":"2023","journal-title":"eJHaem"},{"issue":"14","key":"10.1016\/j.leukres.2025.108086_bib10","doi-asserted-by":"crossref","first-page":"3348","DOI":"10.1080\/10428194.2021.1957869","article-title":"Clinico-genomic profiling and clonal dynamic modeling of tp53 -aberrant myelodysplastic syndrome and acute myeloid leukemia","volume":"62","author":"Patel","year":"2021","journal-title":"Leuk. Lymphoma"},{"issue":"1","key":"10.1016\/j.leukres.2025.108086_bib11","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/s41408-024-01000-2","article-title":"Comparing venetoclax in combination with hypomethylating agents to hypomethylating agent-based therapies for treatment naive TP53-mutated acute myeloid leukemia: results from the consortium on myeloid malignancies and neoplastic diseases (COMMAND)","volume":"14","author":"Badar","year":"2024","journal-title":"Blood Cancer J."},{"issue":"11","key":"10.1016\/j.leukres.2025.108086_bib12","first-page":"3533","article-title":"Prognostic impact of \u201cmulti-hit\u201d versus \u201csingle-hit\u201d tp53 alteration in patients with acute myeloid leukemia: results from the consortium on myeloid malignancies and neoplastic diseases","volume":"109","author":"Badar","year":"2024","journal-title":"Haematologica"},{"issue":"6","key":"10.1016\/j.leukres.2025.108086_bib13","first-page":"1304","article-title":"Clinical interrogation of TP53 aberrations and its impact on survival in patients with myeloid neoplasms","volume":"110","author":"Senapati","year":"2025","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/j.leukres.2025.108086_bib14","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S1470-2045(09)70003-8","article-title":"Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study","volume":"10","author":"Fenaux","year":"2009","journal-title":"Lancet Oncol."},{"issue":"10","key":"10.1016\/j.leukres.2025.108086_bib15","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1200\/JCO.2002.04.117","article-title":"Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group b","volume":"20","author":"Silverman","year":"2002","journal-title":"J. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.leukres.2025.108086_bib16","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1002\/cncr.21792","article-title":"Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study","volume":"106","author":"Kantarjian","year":"2006","journal-title":"Cancer"},{"issue":"21","key":"10.1016\/j.leukres.2025.108086_bib17","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1200\/JCO.2011.38.9429","article-title":"Multicenter, randomized, Open-Label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or Low-Dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia","volume":"30","author":"Kantarjian","year":"2012","journal-title":"J. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.leukres.2025.108086_bib18","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N. Engl. J. Med"},{"issue":"1","key":"10.1016\/j.leukres.2025.108086_bib19","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1080\/10428194.2016.1180688","article-title":"Treatment patterns and comparative effectiveness in elderly acute myeloid leukemia patients (age 70 years or older): the Lyon-university hospital experience","volume":"58","author":"Heiblig","year":"2017","journal-title":"Leuk. Lymphoma"},{"issue":"7","key":"10.1016\/j.leukres.2025.108086_bib20","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1007\/s00277-015-2351-x","article-title":"Big data analysis of treatment patterns and outcomes among elderly acute myeloid leukemia patients in the United States","volume":"94","author":"Medeiros","year":"2015","journal-title":"Ann. Hematol."},{"issue":"2","key":"10.1016\/j.leukres.2025.108086_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.bneo.2024.100016","article-title":"Venetoclax and hypomethylating agents in octogenarians and nonagenarians with acute myeloid leukemia","volume":"1","author":"Madarang","year":"2024","journal-title":"Blood Neoplasia"},{"issue":"11","key":"10.1016\/j.leukres.2025.108086_bib22","doi-asserted-by":"crossref","DOI":"10.1002\/ajh.25949","article-title":"Improved outcomes of octogenarians and nonagenarians with acute myeloid leukemia in the era of novel therapies","volume":"95","author":"Jeng","year":"2020","journal-title":"Am. J. Hematol."},{"issue":"6","key":"10.1016\/j.leukres.2025.108086_bib23","doi-asserted-by":"crossref","DOI":"10.1002\/ajh.25464","article-title":"Treatment patterns and outcomes of octogenarian patients with acute myeloid leukemia","volume":"94","author":"Bhatt","year":"2019","journal-title":"Am. J. Hematol."},{"issue":"1","key":"10.1016\/j.leukres.2025.108086_bib24","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.jclinepi.2011.03.014","article-title":"Accuracy of hospital morbidity data and the performance of comorbidity scores as predictors of mortality","volume":"65","author":"Mnatzaganian","year":"2012","journal-title":"J. Clin. Epidemiol."},{"issue":"3","key":"10.1016\/j.leukres.2025.108086_bib25","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1093\/biomet\/81.3.515","article-title":"Proportional hazards tests and diagnostics based on weighted residuals","volume":"81","author":"Grambsch","year":"1994","journal-title":"Biometrika"},{"issue":"5","key":"10.1016\/j.leukres.2025.108086_bib26","doi-asserted-by":"crossref","first-page":"e239","DOI":"10.1016\/j.clml.2020.01.015","article-title":"Survival of older adults with newly diagnosed acute myeloid leukemia: effect of using multiagent versus Single-agent chemotherapy","volume":"20","author":"Bhatt","year":"2020","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"issue":"ement_1","key":"10.1016\/j.leukres.2025.108086_bib27","doi-asserted-by":"crossref","first-page":"3840","DOI":"10.1182\/blood-2019-131233","article-title":"Epidemiology and survival outcomes in elderly acute myeloid leukemia patients: an NCDB study","volume":"134","author":"Rangoonwala","year":"2019","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.leukres.2025.108086_bib28","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1002\/cncr.30029","article-title":"Sex disparities in use of chemotherapy and survival in patients with advanced bladder cancer","volume":"122","author":"Rose","year":"2016","journal-title":"Cancer"},{"key":"10.1016\/j.leukres.2025.108086_bib29","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.oraloncology.2019.05.009","article-title":"Gender disparities in head and neck cancer chemotherapy clinical trials participation and treatment","volume":"94","author":"Benchetrit","year":"2019","journal-title":"Oral. Oncol."},{"issue":"5","key":"10.1016\/j.leukres.2025.108086_bib30","doi-asserted-by":"crossref","first-page":"503","DOI":"10.6004\/jnccn.2023.0025","article-title":"Acute myeloid leukemia, version 3.2023, NCCN clinical practice guidelines in oncology","volume":"21","author":"Pollyea","year":"2023","journal-title":"J. Natl. Compr. Canc Netw."},{"issue":"11","key":"10.1016\/j.leukres.2025.108086_bib31","doi-asserted-by":"crossref","first-page":"3359","DOI":"10.1007\/s00432-021-03756-7","article-title":"Patterns of undertreatment among patients with acute myeloid leukemia (AML): considerations for patients eligible for non-intensive chemotherapy (NIC)","volume":"147","author":"Hubscher","year":"2021","journal-title":"J. Cancer Res Clin. Oncol."},{"issue":"2","key":"10.1016\/j.leukres.2025.108086_bib32","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/s41375-018-0312-9","article-title":"Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome","volume":"33","author":"Cortes","year":"2019","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.leukres.2025.108086_bib33","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1007\/s00277-021-04465-4","article-title":"Clinical benefit of glasdegib plus low-dose cytarabine in patients with de novo and secondary acute myeloid leukemia: long-term analysis of a phase II randomized trial","volume":"100","author":"Heuser","year":"2021","journal-title":"Ann. Hematol."},{"issue":"4","key":"10.1016\/j.leukres.2025.108086_bib34","first-page":"485","article-title":"Cytosine arabinoside (NSC-63878) and daunorubicin (NSC-83142) therapy in acute nonlymphocytic leukemia","volume":"57","author":"Yates","year":"1973","journal-title":"Cancer Chemother. Rep."},{"issue":"2","key":"10.1016\/j.leukres.2025.108086_bib35","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.bcmd.2012.10.005","article-title":"A historical perspective on the development of the cytarabine (7days) and daunorubicin (3days) treatment regimen for acute myelogenous leukemia: 2013 the 40th anniversary of 7+3","volume":"50","author":"Lichtman","year":"2013","journal-title":"Blood Cells Mol. Dis."},{"issue":"21","key":"10.1016\/j.leukres.2025.108086_bib36","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1056\/NEJMoa1605949","article-title":"tp53 and decitabine in acute myeloid leukemia and myelodysplastic syndromes","volume":"375","author":"Welch","year":"2016","journal-title":"N. Engl. J. Med"},{"issue":"7","key":"10.1016\/j.leukres.2025.108086_bib37","doi-asserted-by":"crossref","first-page":"E139","DOI":"10.1002\/ajh.24036","article-title":"Decitabine improves outcomes in older patients with acute myeloid leukemia and higher blast counts","volume":"90","author":"Kadia","year":"2015","journal-title":"Am. J. Hematol."},{"issue":"16","key":"10.1016\/j.leukres.2025.108086_bib38","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1056\/NEJMoa2117344","article-title":"Ivosidenib and azacitidine in idh1 -Mutated acute myeloid leukemia","volume":"386","author":"Montesinos","year":"2022","journal-title":"N. Engl. J. Med"},{"issue":"11","key":"10.1016\/j.leukres.2025.108086_bib39","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1016\/S1470-2045(21)00494-0","article-title":"Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 trial","volume":"22","author":"DiNardo","year":"2021","journal-title":"Lancet Oncol."},{"issue":"17","key":"10.1016\/j.leukres.2025.108086_bib40","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1182\/blood.2021014586","article-title":"Phase 3 trial of gilteritinib plus azacitidine vs azacitidine for newly diagnosed flt3 mut+ AML ineligible for intensive chemotherapy","volume":"140","author":"Wang","year":"2022","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.leukres.2025.108086_bib41","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1200\/JCO.2015.64.0060","article-title":"Gemtuzumab ozogamicin versus best supportive care in older patients with newly diagnosed acute myeloid leukemia unsuitable for intensive chemotherapy: results of the randomized phase III EORTC-GIMEMA AML-19 trial","volume":"34","author":"Amadori","year":"2016","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.leukres.2025.108086_bib42","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1002\/cam4.321","article-title":"Efficacy and tolerability of treatment with azacitidine for 5 days in elderly patients with acute myeloid leukemia","volume":"3","author":"Sadashiv","year":"2014","journal-title":"Cancer Med"},{"issue":"13","key":"10.1016\/j.leukres.2025.108086_bib43","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1182\/blood-2017-06-788497","article-title":"Randomized phase 2 study of low-dose decitabine vs low-dose azacitidine in lower-risk MDS and MDS\/MPN","volume":"130","author":"Jabbour","year":"2017","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.leukres.2025.108086_bib44","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200034","article-title":"Low-Dose decitabine versus Low-Dose azacitidine in Lower-Risk MDS","volume":"1","author":"Sasaki","year":"2022","journal-title":"NEJM Evid."},{"issue":"8","key":"10.1016\/j.leukres.2025.108086_bib45","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1002\/ajh.24767","article-title":"Early mortality and overall survival of acute myeloid leukemia based on facility type","volume":"92","author":"Bhatt","year":"2017","journal-title":"Am. J. Hematol."},{"issue":"23","key":"10.1016\/j.leukres.2025.108086_bib46","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","article-title":"Genomic classification and prognosis in acute myeloid leukemia","volume":"374","author":"Papaemmanuil","year":"2016","journal-title":"N. Engl. J. Med"},{"issue":"9","key":"10.1016\/j.leukres.2025.108086_bib47","doi-asserted-by":"crossref","first-page":"e65","DOI":"10.1097\/MLR.0b013e318297429c","article-title":"Why summary comorbidity measures such as the charlson comorbidity index and elixhauser score work","volume":"53","author":"Austin","year":"2015","journal-title":"Med Care"},{"issue":"12","key":"10.1016\/j.leukres.2025.108086_bib48","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/j.clml.2020.07.002","article-title":"Usefulness of charlson comorbidity index to predict early mortality and overall survival in older patients with acute myeloid leukemia","volume":"20","author":"Dhakal","year":"2020","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"issue":"4","key":"10.1016\/j.leukres.2025.108086_bib49","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1111\/bjh.19336","article-title":"The heart of VIALE-A: cardiac complications of hypomethylating agents and venetoclax in acute myeloid leukaemia","volume":"204","author":"Patel","year":"2024","journal-title":"Br. J. Haematol."},{"issue":"26","key":"10.1016\/j.leukres.2025.108086_bib50","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1056\/NEJMoa1408617","article-title":"Age-Related clonal hematopoiesis associated with adverse outcomes","volume":"371","author":"Jaiswal","year":"2014","journal-title":"N. Engl. J. Med"},{"issue":"2","key":"10.1016\/j.leukres.2025.108086_bib51","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1056\/NEJMoa1701719","article-title":"Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease","volume":"377","author":"Jaiswal","year":"2017","journal-title":"N. Engl. J. Med"},{"issue":"5","key":"10.1016\/j.leukres.2025.108086_bib52","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1111\/bjh.19423","article-title":"Natural history of clonal haematopoiesis seen in real-world haematology settings","volume":"204","author":"Patel","year":"2024","journal-title":"Br. J. Haematol."},{"issue":"9","key":"10.1016\/j.leukres.2025.108086_bib53","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1080\/10428194.2023.2224473","article-title":"Precision and strategic targeting of novel mutation-specific vulnerabilities in acute myeloid leukemia: the semi-centennial of 7 + 3","volume":"64","author":"Patel","year":"2023","journal-title":"Leuk. Lymphoma"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014521262500476X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014521262500476X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T08:31:25Z","timestamp":1762245085000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S014521262500476X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":53,"alternative-id":["S014521262500476X"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2025.108086","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment patterns and survival outcomes for very elderly patients with acute myeloid leukemia: A National Cancer Database study","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2025.108086","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"108086"}}